Lipid profile improvements (TRIUMPH-4): Non-HDL cholesterol: Clinically meaningful reduction Triglycerides: Significant reduction hsCRP (inflammatory marker): Significant reduction HDL cholesterol: Not significantly improved (consistent with Phase 2 findings) The triglyceride reduction is particularly notable and likely related to glucagon receptor activation, which enhances fat oxidation
The only FDA-approved oral form is Rybelsus, manufactured by Novo Nordisk for Type 2 diabetes
In addition to this, the pre-injection preparation procedure can be somewhat complex
doi:10.1016/j.molmet.2018.09.009
stbring K, Sjholm I, Srenson H, Ekholm A, Erlanson-Albertsson C, Rayner M
Frequently Asked Questions Can I continue GLP-1 therapy if I develop GERD while taking Ozempic or semaglutide